🔎 Trials Near Me

Hjem › Akut lymfoblastisk leukemi › Washington › Seattle

Kliniske studier for Akut lymfoblastisk leukemi i Seattle, WA

21 studier for Akut lymfoblastisk leukemi søker deltakere på steder i og rundt Seattle (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.

Offisiell studietekst (engelsk)

Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →

A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...

Rekrutterer
  • Seattle Children's, University of Washington, Seattle
  • Fred Hutchinson Cancer Research Center, Seattle
Alder 1 til 25 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT05621291

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
  • Swedish Medical Center-Ballard Campus, Seattle
  • Swedish Medical Center-Cherry Hill, Seattle
  • Swedish Medical Center-First Hill, Seattle
  • og 1 flere
Alder 40 til 75 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT05334069

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

RekruttererFase 1
  • Fred Hutchinson Cancer Center, Seattle
Alder 12 til 78 · Alle kjønn · Oppdatert 29. sep. 2026 · NCT03802695

A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

RekruttererFase 2
  • Seattle Children's Hospital, Seattle
6 Months · Alle kjønn · Oppdatert 28. sep. 2026 · NCT06514794

Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment

RekruttererObservasjonsstudie
  • Seattle Children's Hospital d/b/a Seattle Children's Research Institute, Seattle
1 Day – 17 Years · Alle kjønn · Oppdatert 14. aug. 2026 · NCT06274788

Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma

RekruttererFase 2
  • Fred Hutch/University of Washington Cancer Consortium, Seattle
Alder 18 og eldre · Alle kjønn · Oppdatert 13. aug. 2026 · NCT07224100

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases

RekruttererFase 2
  • Fred Hutch/University of Washington Cancer Consortium, Seattle
6 Months – 65 Years · Alle kjønn · Oppdatert 22. jul. 2026 · NCT06013423

Multicenter HomeVENT: Home Values and Experiences Navigation Track

RekruttererFrivillige helsepersonell ønskes velkommen
  • Seattle Childrens Hospital, Seattle
Alder 18 og eldre · Alle kjønn · Oppdatert 16. jul. 2026 · NCT06102330

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

RekruttererObservasjonsstudie
  • Fred Hutchinson Cancer Research Center, Seattle
Alle aldre · Alle kjønn · Oppdatert 6. jul. 2026 · NCT01351545

211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia

RekruttererFase 1/2
  • Fred Hutch/University of Washington Cancer Consortium, Seattle
Alder 18 til 75 · Alle kjønn · Oppdatert 22. jun. 2026 · NCT03128034

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

RekruttererFase 1/2
  • Fred Hutch/University of Washington Cancer Consortium, Seattle
Alder 18 til 75 · Alle kjønn · Oppdatert 22. jun. 2026 · NCT03670966

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

RekruttererFase 2Frivillige helsepersonell ønskes velkommen
  • Fred Hutch/University of Washington Cancer Consortium, Seattle
6 Months · Alle kjønn · Oppdatert 29. mai 2026 · NCT04195633

HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

RekruttererFase 1
  • Fred Hutch/University of Washington Cancer Consortium, Seattle
Opp til 80 år · Alle kjønn · Oppdatert 18. mai 2026 · NCT03326921

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

RekruttererObservasjonsstudie
  • Seattle Children's Hospital, Seattle
Alle aldre · Alle kjønn · Oppdatert 18. mai 2026 · NCT01790152

A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)

RekruttererFase 3
  • Ascentage Investigative Site #1806, Seattle
Alder 18 og eldre · Alle kjønn · Oppdatert 30. apr. 2026 · NCT06051409

Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)

RekruttererFase 2
  • Fred Hutch/University of Washington Cancer Consortium, Seattle
Alder 1 til 60 · Alle kjønn · Oppdatert 12. mar. 2026 · NCT03970096

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

RekruttererFase 1
  • Fred Hutchinson Cancer Research Center, Seattle
Alder 18 og eldre · Alle kjønn · Oppdatert 5. nov. 2025 · NCT04260022

Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)

RekruttererFase 1
  • Fred Hutchinson Cancer Center, Seattle
Alder 18 og eldre · Alle kjønn · Oppdatert 15. apr. 2025 · NCT06462365

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

RekruttererFase 1
  • Seattle Children's Hospital, Seattle
Alder 1 til 21 · Alle kjønn · Oppdatert 6. des. 2024 · NCT05476770

Akut lymfoblastisk leukemi-studier i andre byer

Andre studier i Seattle

Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.